{
    "clinical_study": {
        "@rank": "79190", 
        "arm_group": [
            {
                "arm_group_label": "Azithromycin plus ceftriaxone group (AZY+CEF group)", 
                "arm_group_type": "Experimental", 
                "description": "IV azithromycin (500 mg once daily) plus ceftriaxone (1 gram once daily) for 2 to 5 days followed by oral azithromycin (2 x 250 mg once daily) to complete a total of 7 to 10 days of therapy"
            }, 
            {
                "arm_group_label": "Levofloxacin group (LEV group)", 
                "arm_group_type": "Experimental", 
                "description": "IV levofloxacin (500 mg once daily) for a minimum of 2 days followed by oral levofloxacin (500 mg once daily) to complete a total of 7 to 14 days of therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "A trial in which patients over 18 years of age who are hospitalized with community acquired\n      pneumonia and are otherwise eligible for entry into the study are randomly selected to\n      receive one of two treatment regimens. After written informed consent is obtained, patients\n      will receive one of the following two treatment regimens: 1) intravenous administration of\n      azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous\n      administration of levofloxacin followed by levofloxacin tablets. At least four study visits\n      are normally conducted up to approximately one month after starting therapy. The objective\n      of this study is to compare the safety and efficacy of the two treatment regimens."
        }, 
        "brief_title": "Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia", 
        "completion_date": {
            "#text": "June 2002", 
            "@type": "Actual"
        }, 
        "condition": "Community-Acquired Pneumonia (CAP)", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must be 18 years or older.\n\n          -  Patient must be hospitalized and require intravenous therapy for treatment of\n             pneumonia.\n\n          -  Patient must have pneumonia as documented by relevant signs and symptoms and a\n             positive chest X-ray.\n\n          -  Patients cannot have certain underlying diseases or conditions as defined in the\n             study protocol.\n\n        Exclusion Criteria:\n\n          -  Pregnant women, nursing mothers, or women of childbearing potential not practicing\n             adequate contraception.\n\n          -  Known or suspected hypersensitivity or intolerance to any quinolone, penicillin,\n             cephalosporin, or macrolide antibiotic.\n\n          -  Treatment with any systemic antibiotic for 24 hours or longer within 72 hours prior\n             to the baseline visit.\n\n          -  Subjects with clinically significant renal dysfunction.\n\n          -  Subjects with clinically significant hepatic dysfunction.\n\n          -  Subjects with clinically significant cardiovascular disorders."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "219", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035347", 
            "org_study_id": "A0661035"
        }, 
        "intervention": [
            {
                "arm_group_label": "Azithromycin plus ceftriaxone group (AZY+CEF group)", 
                "description": "500 mg once daily", 
                "intervention_name": "IV azithromycin", 
                "intervention_type": "Drug", 
                "other_name": "Zithromax\u00ae"
            }, 
            {
                "arm_group_label": "Azithromycin plus ceftriaxone group (AZY+CEF group)", 
                "description": "1 gram once daily for 2 to 5 days", 
                "intervention_name": "ceftriaxone", 
                "intervention_type": "Drug", 
                "other_name": "Rocephin\u00ae"
            }, 
            {
                "arm_group_label": "Azithromycin plus ceftriaxone group (AZY+CEF group)", 
                "description": "2 x 250 mg once daily", 
                "intervention_name": "oral azithromycin", 
                "intervention_type": "Drug", 
                "other_name": "Zithromax\u00ae"
            }, 
            {
                "arm_group_label": "Levofloxacin group (LEV group)", 
                "description": "500 mg once daily", 
                "intervention_name": "IV levofloxacin", 
                "intervention_type": "Drug", 
                "other_name": "Levaquin\u00ae"
            }, 
            {
                "arm_group_label": "Levofloxacin group (LEV group)", 
                "description": "500 mg once daily", 
                "intervention_name": "oral levofloxacin", 
                "intervention_type": "Drug", 
                "other_name": "Levaquin\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ceftriaxone", 
                "Ofloxacin", 
                "Azithromycin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 25, 2011", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661035&StudyName=Intravenous%20Azithromycin%20Plus%20Intravenous%20Ceftriaxone%20Followed%20by%20Oral%20Azithromycin%20With%20Intravenous%20Levofloxacin%20Followed%20by%20Oral%20Levofloxacin%"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90822"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sylmar", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91342"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34339"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31902"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31904"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft Gordon", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30905"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shawnee Mission", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66204"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40206"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Royal Oak", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48073-6769"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kirkwood", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63122"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87108-5154"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mineola", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11501"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10003"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27103"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43202"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19140"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sellersville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18960"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba", 
                        "zip": "R3A 1R9"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3H 3A7"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 1C3"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4G5"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1Y 4E9"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H1T 2M4"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ste-foy", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G1V 4G5"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Regina", 
                        "country": "Canada", 
                        "state": "Saskatchewan", 
                        "zip": "S4P 1Z7"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saskatoon", 
                        "country": "Canada", 
                        "state": "Saskatchewan", 
                        "zip": "S7L 2W1"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotenburg (wuemme)", 
                        "country": "Germany", 
                        "state": "Niedersachsen", 
                        "zip": "D-27356"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "D-14109"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Luedenscheid", 
                        "country": "Germany", 
                        "zip": "D58515"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maroussi. Attikis", 
                        "country": "Greece", 
                        "state": "Athens", 
                        "zip": "15126"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Cataluna", 
                        "zip": "08036"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarrasa", 
                        "country": "Spain", 
                        "state": "Cataluna", 
                        "zip": "08221"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Germany", 
                "Greece", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax\u00ae (Azithromycin) Plus Intravenous Rocephin\u00ae (Ceftriaxone) Followed By Oral Zithromax\u00ae (Azithromycin) With Intravenous Levaquin\u00ae (Levofloxacin) Followed By Oral Levaquin\u00ae (Levofloxacin) For The Treatment Of Moderate To Severely Ill Hospitalized Subjects With Community-Acquired Pneumonia", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_outcome": {
            "measure": "Efficacy of sequential therapy with IV Zithromax\u00ae plus IV Rocephin\u00ae followed by oral Zithromax\u00ae to IV Levaquin\u00ae (levofloxacin) followed by oral Levaquin\u00ae in the treatment of moderate to severely ill subjects with community-acquired pneumonia.", 
            "safety_issue": "No", 
            "time_frame": "Duration of trial"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035347"
        }, 
        "responsible_party": {
            "name_title": "Director, Clinical Trial Disclosure Group", 
            "organization": "Pfizer, Inc."
        }, 
        "secondary_outcome": {
            "measure": "Safety and toleration of IV Zithromax\u00ae plus IV Rocephin\u00ae followed by oral Zithromax\u00ae  to IV Levaquin\u00ae followed by oral Levaquin\u00ae, and to compare the bacteriological response rates in subjects with a baseline pathogen.", 
            "safety_issue": "No", 
            "time_frame": "Duration of trial"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2011"
    }, 
    "geocoordinates": {
        "Pfizer Investigational Site": "41.561 2.01"
    }
}